Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with ...
Hosted on MSN1mon
GCTK Stock Plummets to 52-Week Low of $0.06 Amid Market TurbulenceIn a stark reflection of the challenges facing the tech sector, GCTK's stock has tumbled to a 52-week low, touching down at a mere $0.06, with a market capitalization shrinking to just $0.99 million.
Hosted on MSN1mon
Glucotrack soars on completion of first human clinical study of continuous blood glucose monitorGlucotrack (NASDAQ:GCTK) on Tuesday reported the successful completion of its first in human clinical study, sending shares up ~60% in the morning trade. This study represents first real-time ...
(RTTNews) - Glucotrack, Inc. (GCTK), a medical technology company focused on innovative diabetes solutions, on Tuesday announced the successful completion of its first in-human clinical study for ...
15d
(Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Guillermo Umpierrez, MD, CDCES, ...
Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and ...
RUTHERFORD, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the ...
Leading diabetes researcher and clinician joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technologyRUTHERFORD, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback